On October 1, 2022 Takura’s affiliate CuraCell reported the company signes collaboration agreement with Zellwerk-Berlin, a Specialized Contract Development & Manufacturing Organization (CDMO) with engagements in Tumor Infiltrating Lymphocytes (TIL), Natural Killer (NK) cells and Mesenchymal Stromal Cells (MSC), an affiliate of Hiper Group. CuraCell acquires intellectual property rights from Zellwerk Berlin associated with CuraCell’s TIL product, CC-38.
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
CC-38 has been used in patient named treatments in Germany demonstrating promising clinical results. The two companies will now join forces in optimizing and validating CC-38 for upcoming clinical trials. Through the collaboration CuraCell gets access to process engineering capabilities of Zellwerk Berlin’s R&D team and secures manufacturing capacity for its first clinical phase.
(Press release, CuraCell, OCT 1, 2022, View Source [SID1234661184])